MAPT and tauopathy: At present, due to the toxicity or lack of efficacy of other anti-tau therapies, most of the tau targeted therapies undergoing clinical trials are immune-based therapies.531 Sigurdsson’s group was the first to report successful tau targeted therapy based on active and passive immunization against tau, which reduced pathological tau levels and attenuated the behavioral phenotypes associated with tauopathy.532 These results were later confirmed by other groups.